FTC Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, a commission may be earned at no additional cost to you. Editorial content is not influenced by affiliate relationships. MedFoundationNC.org is an independent publication — not a medical practice, hospital, or healthcare provider.
All medications discussed in this article are prescription drugs manufactured by Eli Lilly (Foundayo, Zepbound) and Novo Nordisk (Wegovy). This article is not medical advice. Consult your physician before starting, stopping, or changing any medication.
By MedFoundationNC.org Editorial Team | Last Updated: April 9, 2026
You've heard about Foundayo, Lilly's new weight loss pill. You know about the Wegovy pill that launched a few months earlier. And you're probably already familiar with Zepbound, the injectable that's been getting results since 2023. Now you need to figure out which one — if any — fits your situation. Not which one is “best” in the abstract, but which one works for your body, your budget, your insurance, and your daily life.
This comparison uses published clinical trial data, FDA-approved prescribing information, and verified pricing as of April 2026. Where head-to-head data doesn't exist — and for most of these comparisons, it doesn't — we say so explicitly. If you're searching for Foundayo vs Ozempic or Foundayo vs Mounjaro, keep in mind that Ozempic and Mounjaro are approved for type 2 diabetes, not weight management — Wegovy and Zepbound are their weight-loss counterparts from the same manufacturers. The orforglipron weight loss data below reflects Foundayo's obesity indication specifically.
The Three Options at a Glance
Foundayo (orforglipron) — manufactured by Eli Lilly. Once-daily oral pill. Non-peptide small-molecule GLP-1 receptor agonist. FDA approved April 1, 2026. No food or water restrictions. No refrigeration required. Six dose levels from 0.8 mg to 17.2 mg.
Wegovy Pill (oral semaglutide) — manufactured by Novo Nordisk. Once-daily oral pill. Peptide-based GLP-1 receptor agonist. FDA approved December 2025. Must be taken on an empty stomach first thing in the morning with no more than 4 ounces of water. Must wait 30 minutes before eating, drinking, or taking other medications. No refrigeration required.
Zepbound (tirzepatide) — manufactured by Eli Lilly. Once-weekly subcutaneous injection. Dual GIP/GLP-1 receptor agonist. FDA approved November 2023. Requires refrigeration before first use. Five dose levels from 2.5 mg to 15 mg. If you're searching for a Foundayo vs Zepbound comparison, it's important to understand that these are fundamentally different drugs from the same company — different active ingredient, different mechanism, different delivery method.
Weight Loss: What the Published Data Shows
Important caveat first: no single clinical trial has compared all three of these medications head-to-head at their FDA-approved obesity doses. The numbers below come from separate clinical programs with different patient populations, trial designs, and measurement timeframes. They provide a reasonable framework for comparison — but they aren't perfectly equivalent.
Foundayo: In the ATTAIN-1 trial, participants on the highest dose who completed 72 weeks of treatment lost an average of 12.4% of their starting body weight (27.3 pounds), compared to 0.9% (2.2 pounds) for placebo. The treatment-regimen analysis (all randomized patients) showed 11.2% (25.0 pounds) versus 2.1% (5.3 pounds).
Wegovy Pill: In published trial data, patients taking 25 mg oral semaglutide lost approximately 17% of their body weight over 64 weeks. Published data also shows that about 55% of patients on the highest dose achieved 15% or more weight loss.
Zepbound: In its primary Phase 3 trial, patients on the highest dose (15 mg) who completed 72 weeks lost approximately 21% of their body weight. This is currently the highest average weight loss published for any FDA-approved GLP-1 medication.
The weight loss gap is real. If you're optimizing purely for maximum weight reduction, the published numbers favor Zepbound, followed by the Wegovy pill, then Foundayo. But weight loss numbers from a controlled clinical trial don't automatically predict what will happen in your life — adherence, tolerability, and consistency matter enormously, and those are the areas where the oral options may have practical advantages.
Convenience and Daily Experience
This is where Foundayo has a genuine competitive advantage over both alternatives.
Foundayo: Take it whenever you want. With food, without food. Morning, evening, middle of the afternoon. No fasting. No water restrictions. Store it in a medicine cabinet. Travel with it in your bag. According to the published prescribing information, there are no timing or dietary constraints whatsoever.
Wegovy Pill: Take it first thing in the morning. Empty stomach. No more than 4 ounces of water. Wait 30 minutes before food, drink, coffee, or other medications. Every single day. This isn't impossible — more than 170,000 people were taking the Wegovy pill as of February 2026, according to Novo Nordisk — but it requires a daily routine adjustment that some patients find burdensome over months and years of use.
Zepbound: Once-weekly injection. Easier frequency than a daily pill, but it requires comfortable self-injection, refrigerated storage before first use, and travel planning around temperature-sensitive medication. Some patients prefer the once-a-week schedule. Others find the injection itself — and the logistics around it — to be the primary barrier.
Foundayo Cost vs Wegovy Pill Cost vs Zepbound Cost
Pricing in the GLP-1 market is complicated by insurance coverage, manufacturer savings programs, and the difference between list price and what you actually pay. Here's the published pricing as of April 2026:
Foundayo self-pay: $149/month (0.8 mg), $199/month (2.5 mg), $299/month (5.5 mg and above). With commercial insurance and savings card: as low as $25/month. Medicare Part D: approximately $50/month starting July 2026.
Wegovy Pill self-pay: Starts at $149/month at the lowest dose through NovoCare, Novo Nordisk's direct-to-consumer platform. Higher doses range up to $299/month. Similar savings card programs are available for commercially insured patients.
Zepbound self-pay: $299/month through LillyDirect. With commercial insurance and savings card: as low as $25/month. Zepbound's list price without any discounts is significantly higher.
At the entry level, both pills are priced identically at $149. At maintenance doses, both pills range up to $299-$349 depending on the specific dose. Zepbound starts at $299 for cash-pay customers. In practice, what you actually pay will depend almost entirely on your insurance situation and whether you qualify for manufacturer discount programs.
For readers for whom even the lowest FDA-approved pricing is out of reach, compounded GLP-1 alternatives available through telehealth platforms offer lower price points — with different regulatory frameworks and different levels of published clinical evidence. Our reviews of MEDVi, TrimRx, and Direct Meds cover what those programs offer, what they cost, and what to verify before enrolling.
Side Effects: How the Three Compare
All three medications share a common side effect profile rooted in the GLP-1 mechanism: nausea, constipation, diarrhea, vomiting, and other gastrointestinal effects are the most commonly reported adverse events across all three drugs. All three carry the same boxed warning regarding thyroid C-cell tumors and the same contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN2.
Some differences are worth noting. Zepbound — as a dual GIP/GLP-1 agonist — has a slightly different pharmacological profile that some patients tolerate differently from single-mechanism GLP-1 drugs. The Wegovy pill's fasting requirement means GI side effects may be influenced by whether the patient follows the dosing instructions correctly. Foundayo's non-peptide chemistry means it interacts with the CYP3A4 enzyme system, creating drug interaction considerations (particularly with simvastatin and strong CYP3A4 inhibitors) that don't apply to the peptide-based medications. For the full Foundayo safety profile including drug interactions, our side effects and safety guide has the published prescribing data.
Injectable medications carry the additional consideration of injection site reactions, which don't apply to either oral option.
The Maintenance Question: Who's Best for Long-Term Use
This is where the conversation gets strategic. Eli Lilly has published Phase 3 data showing that patients who lost weight on injectable GLP-1 therapy were able to maintain that weight loss after switching to Foundayo. That creates a treatment pathway that wasn't available before: start aggressive with an injectable, hit your target weight, then step down to an oral pill for long-term maintenance at a lower cost and with a simpler routine.
This injectable-to-oral transition model is new enough that most insurance plans haven't built coverage pathways around it yet. But the clinical evidence supports it, and physicians are beginning to incorporate it into treatment planning. If you're currently on Zepbound or Wegovy injections and approaching your target weight, this is a conversation worth having with your provider. If you're on an injectable and finding that results have stalled before reaching your target, our guide to when GLP-1 injections stop working covers common reasons and what to try next.
How to Decide: Matching the Medication to Your Situation
Choose Foundayo if: You haven't tried a GLP-1 medication before and want the simplest possible entry point. You prioritize no-fasting convenience. You're looking for an FDA-approved option at a lower price point than injectables. You're transitioning from an injectable and want to maintain weight loss with an oral pill.
Choose the Wegovy Pill if: You're comfortable with a morning fasting routine and want to potentially maximize weight loss from an oral option. Published data suggests the Wegovy pill produces slightly more average weight loss than Foundayo, though the difference is modest and no direct head-to-head trial at obesity doses has been published.
Choose Zepbound if: Maximum weight loss is your primary goal and you're comfortable with weekly self-injection. You don't mind refrigerated storage and injection logistics. Your insurance covers it. Published data shows Zepbound produces the highest average weight loss of any currently available option.
Explore compounded alternatives if: You can't access or afford FDA-approved options and you understand the regulatory and clinical-evidence differences. Our coverage of MEDVi, TrimRx, and Direct Meds can help you evaluate those platforms.
No article can tell you which GLP-1 medication is right for you — that decision involves your BMI, your health conditions, your current medications, your budget, and your daily life. What we can tell you is that as of April 2026, you have more FDA-approved options than at any point in the history of obesity medicine, and they're more accessible and more affordable than they've ever been. Start the conversation with a licensed healthcare provider who knows your complete medical picture. For a full breakdown of Foundayo specifically — clinical data, pricing, access channels, and who it's for — our Foundayo 2026 guide has everything you need. For the broader picture of how pills and injections compare across the full GLP-1 market, our GLP-1 pills vs injections guide covers that ground.
Published April 9, 2026. MedFoundationNC.org Editorial Team.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Foundayo, Zepbound, Wegovy, Ozempic, and Mounjaro are prescription medications manufactured by Eli Lilly and Company and Novo Nordisk. All clinical data cited in this article is attributed to published trial results, FDA-approved labeling, or verified manufacturer disclosures. Individual results vary. No head-to-head trial has compared all three medications at their FDA-approved obesity doses — cross-trial comparisons have limitations. Consult a licensed healthcare provider about your specific health situation. Pricing, coverage, and availability information is based on published sources as of April 2026 and is subject to change. MedFoundationNC.org is an independent editorial publication — not a medical practice, hospital, or healthcare provider.